Zur Behandlung der weiblichen Urge-Inkontinenz durch lokale Östrogentherapie

Enzelsberger, H.; Schatten, Ch.; Kurz, Ch.; Zorzi, Patrícia de Moraes De

doi:10.1159/000271457

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up until the present study the only publications on the efficacy of vaginal estriol cream have featured small sample size ( N = 10–44) Most had no sample size calculations or objective outcome measures 13–18 …”

Section: Discussionmentioning

confidence: 88%

“…Up until the present study the only publications on the efficacy of vaginal estriol cream have featured small sample size (N = 10-44) Most had no sample size calculations or objective outcome measures. [13][14][15][16][17][18] During a previous 6-week study published, 5 6 weeks was chosen for pragmatic reasons (as this was the waiting time for a first physiotherapy appointment in the trial centers) thus, the duration of treatment was not optimal. Therefore, this current study represents the first study with the correct dosage and duration, where validated outcome measures were used in an adequate sample size.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of 12 weeks of estriol cream on stress urinary incontinence post‐menopause: A prospective multinational observational study

West

Jeffrey

Nie

et al. 2023

Neurourology and Urodynamics

View full text Add to dashboard Cite

Objective: To quantitate the changes in stress urinary incontinence (SUI) outcome measures after 12 weeks of vaginal estriol cream in women with stress incontinence. Methods:A prospective multicentre observational study conducted in tertiary urogynaecology centers. Postmenopausal women with pure SUI or stress predominant mixed urinary incontinence (MUI), not receiving any other treatment for their incontinence were given written instructions regarding digital application of a standard dose of vaginal estriol cream. Outcomes were measured at baseline and 12 weeks. The primary objective outcome was vaginal pH. The primary subjective outcome was the stress domain of the Urogenital Distress Inventory-6 (UDI-6). The secondary objective outcome used was the erect cough stress test.Two quality of life questionnaires and two patient reported outcomes were also included. Results: The 46 postmenopausal recruits had a median age of 62.1 interquartile range ). At follow up, the primary subjective outcome SUI domain [UDI-6] significantly improved from 83.3 (IQR 50-100) to 33.3 (33.3-66.7, p ≤ 0.001) as did vaginal pH [from 5.1 (4.9-5.9) to 4.9 (4.6-5.0] p ≤ 0.001; 18/43 patients (42%) were dry on cough stress test.Conclusions: Twelve weeks of vaginal estriol cream significantly reduced symptoms of stress urinary incontinence in this sample of postmenopausal women.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

The effect of 12 weeks of estriol cream on stress urinary incontinence post‐menopause: A prospective multinational observational study

West

Jeffrey

Nie

et al. 2023

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…There were no long-term data available and no data on effect after stopping treatment. One trial included in the Cochrane analysis indicated a dose relationship with significantly higher bladder capacity and fewer nocturnal as well as total voids with higher doses of local E3 cream when comparing 0.5 and 1-2 mg and comparing 1-3 mg intravaginally [27,28].…”

Section: Urinary Atrophy Urinary Incontinence and Utimentioning

confidence: 99%

“…However, no comparisons with lubricants or moisturizers are available with the new very-low-dose treatment with 10 µg E2. Only three studies compare different doses of the same treatment [19,27,28]. From these studies, there may be a dose relationship in the treatment of urogenital atrophy although no firm conclusions can be made.…”

Section: Reviewmentioning

confidence: 99%

The role of local vaginal estrogen treatment in urogenital atrophy

Ulrich

2012

Expert Review of Obstetrics & Gynecology

View full text Add to dashboard Cite

This is a review of currently available data on local vaginal estrogen treatment with critical comments and a view on future perspectives. Vaginal atrophy affects 25-50% of postmenopausal women, and 40-45% of sexually active women suffer from dyspareunia. Treatment with all available local estrogen preparations is effective, but studies on dose-response relationship are lacking as is noncompany-sponsored comparisons between different estrogens and formulations. Local estrogen is effective in the prevention of recurrent urinary tract infection, but data on incontinence are mixed. Epidemiological data, long-term clinical safety data and data in women with a history of breast and other cancers are lacking. Safety data beyond 1 year are needed to support actual use. The use of local therapy is still likely to increase. The role of local vaginal estrogen treatment in urogenital atrophyExpert Rev. Obstet. Gynecol. 7(6), 545-556 (2012)

show abstract